enVVeno Medical Corporation
enVVeno Medical Corporation (HJLI) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for enVVeno Medical Corporation (HJLI), covering cash flow, earnings, and balance sheets.
enVVeno Medical Corporation (HJLI) Income Statement & Financial Overview
Analyze enVVeno Medical Corporation’s HJLI earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $812000.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $406000.00 | $129000.00 | $136000.00 | $141000.00 |
| Gross Profit | $406000.00 | -$129000.00 | -$136000.00 | -$141000.00 |
| Gross Profit Ratio | $0.50 | $0.00 | $0.00 | $0.00 |
| R&D Expenses | $3.51M | $2.86M | $2.83M | $3.05M |
| SG&A Expenses | $3.46M | $3.31M | $2.49M | $2.31M |
| Operating Expenses | $6.98M | $6.17M | $5.32M | $5.36M |
| Total Costs & Expenses | $7.38M | $6.17M | $5.45M | $5.50M |
| Interest Income | $163000.00 | $94000.00 | $73000.00 | $59000.00 |
| Interest Expense | $389000.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | -$406000.00 | $129000.00 | $136000.00 | $141000.00 |
| EBITDA | -$6.73M | -$6.04M | -$5.32M | -$5.36M |
| EBITDA Ratio | -$8.29 | $0.00 | $0.00 | $0.00 |
| Operating Income | -$6.70M | -$6.17M | -$5.45M | -$5.50M |
| Operating Income Ratio | -$8.25 | $0.00 | $0.00 | $0.00 |
| Other Income/Expenses (Net) | $470000.00 | $528000.00 | $498000.00 | $511000.00 |
| Income Before Tax | -$6.23M | -$5.64M | -$4.96M | -$4.99M |
| Income Before Tax Ratio | -$7.67 | $0.00 | $0.00 | $0.00 |
| Income Tax Expense | -$97724.00 | $0.00 | $0.00 | $97724.00 |
| Net Income | -$6.23M | -$5.64M | -$4.96M | -$4.99M |
| Net Income Ratio | -$7.67 | $0.00 | $0.00 | $0.00 |
| EPS | $0.91 | -$0.35 | -$0.31 | -$0.31 |
| Diluted EPS | $0.91 | -$0.35 | -$0.31 | -$0.31 |
| Weighted Avg Shares Outstanding | $17.14M | $16.07M | $16.07M | $16.06M |
| Weighted Avg Shares Outstanding (Diluted) | $17.14M | $16.07M | $16.07M | $16.06M |
Over the past four quarters, enVVeno Medical Corporation demonstrated steady revenue growth, increasing from $0.00 in Q1 2024 to $812000.00 in Q4 2024. Operating income reached -$6.70M in Q4 2024, maintaining a consistent -825% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$6.73M, reflecting operational efficiency. Net income dropped to -$6.23M, with EPS at $0.91. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan